GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Korean Diabetes Association  (3)
  • Kim, Hwi Seung  (3)
Material
Publisher
  • Korean Diabetes Association  (3)
Language
Years
  • 1
    In: Diabetes & Metabolism Journal, Korean Diabetes Association, Vol. 46, No. 4 ( 2022-07-31), p. 658-662
    Abstract: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) are novel anti-diabetic drugs whose glucose-lowering effect and cardiovascular and renal benefits were evidenced in clinical trials. We investigated the real-world efficacy and safety of the combination of SGLT2i and GLP-1RA in patients with type 2 diabetes mellitus in Korea. The medical records of 104 patients who maintained the combination for at least 1 year were retrospectively reviewed. The change in glycosylated hemoglobin (HbA1c) after 6 months and 1 year of treatment was evaluated. The mean age was 51 years, and 41% were female. The mean baseline HbA1c, body mass index, and duration of diabetes were 9.0%, 28.8 kg/m2, and 11.7 years, respectively. Compared with baseline, the HbA1c decreased by 1.5% (95% confidence interval [CI], 1.27 to 1.74; P 〈 0.001) after 6 months and by 1.4% (95% CI, 1.19 to 1.70; P 〈 0.001) after 1 year. Over 1 year, the bodyweight change was −2.8 kg (95% CI, −4.21 to −1.47; P 〈 0.001). The combination of SGLT2i and GLP-1RA is effective and tolerable in type 2 diabetes mellitus patients in real-world practice.
    Type of Medium: Online Resource
    ISSN: 2233-6079 , 2233-6087
    Language: English
    Publisher: Korean Diabetes Association
    Publication Date: 2022
    detail.hit.zdb_id: 2602402-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Diabetes & Metabolism Journal, Korean Diabetes Association, Vol. 47, No. 1 ( 2023-01-31), p. 104-117
    Abstract: Background: The association of myosteatosis measured using visual muscular quality map in computed tomography (CT) with nonalcoholic fatty liver disease (NAFLD), its severity, and fibrosis was analyzed in a large population.Methods: Subjects ( 〈 i 〉 n 〈 /i 〉 =13,452) with abdominal CT between 2012 and 2013 were measured total abdominal muscle area (TAMA) at L3 level. TAMA was segmented into intramuscular adipose tissue and skeletal muscle area (SMA), which was further classified into normal attenuation muscle area (NAMA) and low attenuation muscle area (LAMA). The following variables were adopted as indicators of myosteatosis: SMA/body mass index (BMI), NAMA/BMI, NAMA/TAMA, and LAMA/BMI. NAFLD and its severity were assessed by ultrasonography, and liver fibrosis was measured by calculating the NAFLD fibrosis score (NFS) and fibrosis-4 index (FIB-4) scores.Results: According to multiple logistic regression analyses, as quartiles of SMA/BMI, NAMA/BMI, and NAMA/TAMA increased, the odds ratios (ORs) for NAFLD decreased in each sex ( 〈 i 〉 P 〈 /i 〉 for trend 〈 0.001 for all). The ORs of moderate/severe NAFLD were significantly higher in the Q1 group than in the Q4 group for SMA/BMI, NAMA/BMI, and NAMA/TAMA in men. The ORs of intermediate/high liver fibrosis scores assessed by NFS and FIB-4 scores increased linearly with decreasing quartiles for SMA/BMI, NAMA/BMI, and NAMA/TAMA in each sex ( 〈 i 〉 P 〈 /i 〉 for trend 〈 0.001 for all). Conversely, the risk for NAFLD and fibrosis were positively associated with LAMA/BMI quartiles in each sex ( 〈 i 〉 P 〈 /i 〉 for trend 〈 0.001 for all).Conclusion: A higher proportion of good quality muscle was associated with lower risks of NAFLD and fibrosis.
    Type of Medium: Online Resource
    ISSN: 2233-6079 , 2233-6087
    Language: English
    Publisher: Korean Diabetes Association
    Publication Date: 2023
    detail.hit.zdb_id: 2602402-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Korean Diabetes Association ; 2021
    In:  Diabetes & Metabolism Journal Vol. 45, No. 6 ( 2021-11-30), p. 948-953
    In: Diabetes & Metabolism Journal, Korean Diabetes Association, Vol. 45, No. 6 ( 2021-11-30), p. 948-953
    Abstract: Dulaglutide, a weekly injectable glucagon-like peptide-1 receptor agonist, has demonstrated effectiveness when combined with basal insulin. We examined whether the efficacy of dulaglutide is comparable to that of prandial insulin in kidney transplant (KT) recipients with type 2 diabetes mellitus (T2DM) undergoing multiple daily insulin injection (MDI) therapy. Thirty-seven patients, who switched from MDI therapy to basal insulin and dulaglutide, were retrospectively analyzed. Changes in glycosylated hemoglobin (HbA1c) and fasting plasma glucose (FPG) levels, body weight, and basal insulin dose were evaluated over 6 months. Dulaglutide was comparable to three injections of prandial insulin in terms of glycemic control (HbA1c 7.1% vs. 7.0%; 95% confidence interval [CI], –0.53 to 0.28; P=0.53). The basal insulin and dulaglutide combination resulted in a reduction in FPG levels by 9.7 mg/dL (95% CI, 2.09 to 41.54; P=0.03), in body weight by 4.9 kg (95% CI, 2.87 to 6.98; P 〈 0.001), and in basal insulin dose by 9.52 IU (95% CI, 5.80 to 3.23; P 〈 0.001). Once-weekly dulaglutide may be an effective alternative for thrice-daily prandial insulin in KT recipients with T2DM currently receiving MDI therapy.
    Type of Medium: Online Resource
    ISSN: 2233-6079 , 2233-6087
    Language: English
    Publisher: Korean Diabetes Association
    Publication Date: 2021
    detail.hit.zdb_id: 2602402-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...